Alternative HPV vaccination schedules in Latin America
Open Access
- 13 December 2018
- journal article
- research article
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 60 (6, nov-dic) , 693-702
Abstract
In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clinical efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.Keywords
This publication has 37 references indexed in Scilit:
- Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysisThe Lancet Global Health, 2016
- Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world ExperienceClinical Infectious Diseases, 2016
- Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2015
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in WomenNew England Journal of Medicine, 2015
- Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa RicaPLOS ONE, 2013
- Clinical trials of human papillomavirus vaccines and beyondNature Reviews Clinical Oncology, 2013
- Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: A population-based surveyVaccine, 2012
- Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccinesBest Practice & Research Clinical Obstetrics & Gynaecology, 2011
- Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in PeruVaccine, 2011
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999